Company Soligenix, Inc.

Equities

SNGX

US8342236044

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 10:52:26 2024-09-09 am EDT			5-day change	1st Jan Change
3.790 ^USD	+1.34%		-1.05%	-68.88%

Aug. 18	Transcript : Soligenix, Inc. - Special Call
Aug. 09	Soligenix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI

Business description: Soligenix, Inc.

Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics segment is developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Development programs in this segment also include expansion of synthetic hypericin (SGX302) into psoriasis and dusquetide (SGX942 and SGX945) for the treatment of inflammatory diseases. Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19.

Number of employees: 14

Sales by Activity: Soligenix, Inc.

Fiscal Period: December	2019	2020	2021	2022	2023
Public Health Solutions	3.4M	2.24M	824K	917K	444K
Specialized Biotherapeutics	1.23M	117K	-	31.93K	395K

See all business segments

Geographical breakdown of sales: Soligenix, Inc.

Fiscal Period: December	2019	2020	2021	2022	2023
United States	4.63M	2.36M	824K	949K	839K

See all geographic segments

Managers: Soligenix, Inc.

Director	Title	Age	Since
Christopher Schaber CEO	Chief Executive Officer	57	06-07-31
Jonathan Guarino DFI	Director of Finance/CFO	51	19-09-10
Richard Straube CTO	Chief Tech/Sci/R&D Officer	72	14-01-05
Oreola Donini CTO	Chief Tech/Sci/R&D Officer	52	13-08-14
Adam T. Rumage LAW	General Counsel	-	06-12-31

See SOLIGENIX, INC. governance

Members of the board: Soligenix, Inc.

Manager	Title	Age	Since
Christopher Schaber CEO	Chief Executive Officer	57	06-07-31
Gregg Lapointe BRD	Director/Board Member	65	09-02-28
Robert Rubin BRD	Director/Board Member	78	09-09-30
Jerome Zeldis BRD	Director/Board Member	74	11-06-21
Diane Parks BRD	Director/Board Member	71	19-07-07

Composition of the Board of Directors

Shareholders: Soligenix, Inc.

Name	Equities	%	Valuation
Armistice Capital LLC 3.508 %	80,000	3.508 %	280 000 $
Old National Bank (Investment Management) 0.4385 %	10,000	0.4385 %	35 000 $
UBS Securities LLC 0.2732 %	6,231	0.2732 %	21 809 $
Tower Research Capital LLC 0.1610 %	3,672	0.1610 %	12 852 $
Timothy Coté 0.0694 %	1,582	0.0694 %	5 537 $

List of SOLIGENIX, INC. shareholders

Company details: Soligenix, Inc.

Soligenix, Inc.

29 Emmons Drive Suite B-10

08540-5919, Princeton

+(609) 538-8200

http://www.soligenix.com

Bio Therapeutic Drugs

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
SOLIGENIX, INC.	+1.34%	-1.05%	-53.61%	-98.65%	8.53M
REGENERON PHARMACEUTICALS, INC.	+1.04%	-2.60%	+36.58%	+76.20%	122B
VERTEX PHARMACEUTICALS INCORPORATED	+0.95%	-0.95%	+35.70%	+150.51%	121B
ARGENX SE	+2.36%	+7.36%	+1.50%	+76.36%	32.37B
BIONTECH SE	+4.39%	+6.62%	-20.45%	-73.30%	21.38B
BEIGENE, LTD.	+0.93%	+1.96%	-8.26%	-43.10%	20.33B
GENMAB A/S	+0.03%	-0.72%	-28.40%	-35.08%	17.58B
WUXI APPTEC CO., LTD.	+1.57%	+0.59%	-48.28%	-71.83%	15.54B
VAXCYTE, INC.	+1.47%	+2.57%	+115.54%	+334.72%	13.59B
SAREPTA THERAPEUTICS, INC.	-0.43%	-4.65%	+8.80%	+60.00%	12.29B
Average	+1.37%	+3.77%	+3.91%	+37.58%	37.6B
Weighted average by Cap.	+1.26%	-1.52%	+23.01%	+82.63%